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ABSTRACT
Previous pathologic, intravascular imaging, and clinical studies have investigated the 
association between adverse cardiac events and stent malapposition, including acute stent 
malapposition (ASM, that is detected at index procedure) and late stent malapposition (LSM, 
that is detected during follow-up) that can be further classified into late-persistent stent 
malapposition (LPSM, ASM that remains at follow-up) or late-acquired stent malapposition 
(LASM, newly developed stent malapposition at follow-up that was not present immediately 
after index stent implantation). ASM has not been associated with adverse cardiac events 
compared with non-ASM, even in lesions with large-sized malapposition. The clinical 
outcomes of LSM may depend on its subtype. The recent intravascular ultrasound studies 
with long-term follow-up have consistently demonstrated that LASM steadily increased the 
risk of thrombotic events in patients with first-generation drug-eluting stents (DESs). This 
association has not yet been identified in LPSM. Accordingly, it is reasonable that approaches 
to stent malapposition should be based on its relationship with clinical outcomes. ASM 
may be tolerable after successful stent implantation, whereas prolonged anti-thrombotic 
medications and/or percutaneous interventions to modify LASM may be considered in 
selected patients with first-generation DESs. However, these treatments are still questionable 
due to lack of firm evidences.
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INTRODUCTION
Stent apposition refers to the proximity of struts to the vascular wall.1-3) Good stent 
apposition is sufficiently close contact to preclude blood flow between any strut and the 
underlying artery2) while stent malapposition is separation of any strut from the intimal 
surface of the arterial wall that is not overlapping a side branch.2) The frequency of stent-
vessel wall malapposition after percutaneous coronary intervention varies with the clinical 
scenario, lesion morphology, and the type of stent implanted. Unfortunately, there is a 
lack of agreement as to its importance and clinical impact.1) Early short-term intravascular 
ultrasound (IVUS) studies in small numbers of patients have given way to both long-term 
IVUS studies in larger numbers of patients as well as to detailed, higher resolution optical 
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coherence tomography (OCT) studies. This review provides a comprehensive summary of 
the relationship between coronary stent malapposition and its long-term clinical outcomes 
based on both IVUS and OCT studies.
ACUTE STENT MALAPPOSITION
Definition, prevalence, and mechanisms
The prevalence of acute stent malapposition (ASM), occurring immediately after 
implantation, is higher when assessed using OCT than with IVUS. On IVUS, ASM has been 
reported from 7.3% to 38.5% (averaging approximately 13%); on OCT, the prevalence varies 
from 39.1% to 72.3% (averaging approximately 51%) (Table 1).
There are 2 main mechanisms of ASM.1)4)5) The most common is a stent whose cross-sectional 
area is smaller than that of the surrounding lumen due to an undersized stent or an intra-
stent aneurysmal/ectatic segment or at the proximal edge because of lumen tapering (for 
example, proximal to a side branch when treating a bifurcation lesion). The lesser cause of 
ASM is the transition from non-calcified to calcified plaque (especially a calcified nodule) 
because the expanded stent cannot conform to abrupt changes in lumen geometry.
Clinical outcomes
Table 1 summarizes the clinical outcomes of ASM. To date there has been no dedicated, 
prospective study; and most studies are based on retrospective or sub-group analyses. 
Nevertheless, despite the heterogeneity of study design, patient characteristics, stent types, 
and imaging modalities, studies consistently show that adverse cardiac events do not differ 
between patients with vs without ASM.
The IVUS study by Wang et al.6) included 2,072 patients with 2,446 lesions from ADAPT-
DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study which was 
a prospective, multicenter registry designed to assess the relationship between platelet 
reactivity and other clinical and procedural variables vs subsequent stent thrombosis 
(ST) and adverse clinical events in patients successfully treated with drug-eluting stent 
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Table 1. Studies investigating ASM
Study No. of patients Stent type Imaging Prevalence Follow-up
Adverse cardiac events
ASM Non-ASM Difference
van der Hoeven et al.43) 184 Cypher/BMS IVUS 38.5%/33.8% 1 year No ST No ST No
Guo et al.9) 241 Taxus/BMS IVUS 34.3%/40.3% 1 year No ST No ST No
Steinberg et al.20) 1,580 Taxus Express/Taxus 
Liberté/BMS
IVUS 9.7%/7.3%/7.2% 9 months 0.6% ST for Taxus 1.5% ST for Taxus No
No ST for BMS No ST for BMS No
Wang et al.6) 2,072 DES IVUS 12.6% 2 years 5.2% MACE 4.5% MACE No
Im et al.5) 351 DES OCT 62.1% - - - -
Prati et al.44) 832 DES/BMS/BVS OCT 49.3%* 10 months 13.0% MACE 12.4% MACE No
Soeda et al.45) 786 DES/BMS OCT 39.1% 1 year 4.4% DoCE 4.9% DoCE No
Prati et al.46) 507 DES/BMS/BVS OCT 48.0%* 1 year 12.8% DoCE 11.4% DoCE No
Bernelli et al.47) 114 DES OCT 71.9% - - - -
Ali et al.48) 415 DES OCT 46.5% - - - -
Romagnoli et al.7) 864 DES/BMS/BVS OCT 72.3% 10 months 11.0% MACE 13.0% MACE No
Lee et al.4) 386 DES OCT 69.5% - - - -
Lee et al.8) 436 DES OCT 44.8%† 5 years 2.0% MACE 3.3% MACE No
ASM = acute stent malapposition; BMS = bare metal stent; BVS = bioresorbable vascular scaffold; DES = drug-eluting stent; DoCE = device-oriented clinical end 
point; IVUS = intravascular ultrasound; MACE = major adverse cardiac events; OCT = optical coherence tomography; ST = stent thrombosis.
*Lesions with >200 μm of maximum malapposed distance; †Lesions with ≥400 μm of maximum malapposed distance or ≥1 mm of maximum malapposed length.
(DES). At 2-year follow-up, there was no significant difference in the incidence of cardiac 
death; myocardial infarction; early, late, or very late ST; or clinically driven target lesion 
revascularization in patients with ASM vs those without ASM.6) In fact, the largest areas of 
ASM were not associated with events. These results were consistent even when ASM was 
forced into the multivariable model.6)
The study by Romagnoli et al.7) was the most detailed quantitative OCT analysis to date. It 
analyzed post-procedural OCT findings in 864 patients undergoing percutaneous coronary 
intervention, assessing prevalence and magnitude of ASM and exploring correlation with 
clinical outcomes.7) At a median follow-up of 302 days, ASM did not affect risk of major 
adverse cardiac events (MACE) regardless of its size or length; residual ASM was comparable 
in terms of size (median 210 μm vs 200 μm distance) and length (2.0 mm vs 2.2 mm) in 
patients with vs without MACE.7)
The OCT study by Lee et al.8) was a pooled analysis from 6 small randomized trials and 
included 436 patients with 444 non-complex lesions treated with DES. Adverse cardiac events 
at 5-year follow-up were compared according to the severity, not simply the presence of ASM. 
The rate of MACE was 3.3% in patients with ASM ≥400 μm of maximum malapposed strut 
distance vs 3.1% in those with no ASM or ASM <400 μm (p=0.89) and 1.2% in patients with 
ASM ≥1mm of maximum malapposed strut length vs 4.6% in those with no ASM or ASM 
<1mm of maximum malapposed strut length (p=0.06).8)
Approximately half of ASM resolve at follow-up (Figure 1). Guo et al.9) reported that 40% 
of ASM identified by IVUS resolved at follow-up. Im et al.5) similarly reported that 69% of 
OCT-defined ASM resolved spontaneously. Resolution of ASM depends on its size, especially 
when the distance from the stent to the vessel wall is less than 350–400 μm.5)10)11) Conversely, 
Kolandaivelu et al.12) examined the thrombogenicity of malapposed struts via in vitro 
experiments. In single-strut 2-dimensional simulations with various detachment distances, 
stent-wall recirculation zones, highly thrombogenic areas around struts, first grew in size, 
shifted down-stream, and then lost stent communication.12) However, when the distance 
between stent strut and wall was greater than 320 μm, the recirculation zones became 
smaller and eventually disappeared.12) Thus, smaller ASM resolve while larger ASM may not 
affect the blood flow adjacent to arterial wall and, instead, just float in the lumen like struts 
across the ostium of a side branch.13)
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Figure 1. Resolution of acute stent malapposition assessed by optical coherence tomography. The malapposed 
strut (arrow) at index procedure (left) was resolved at 1 year of follow-up (right) through neointimal integration 
between stent strut and vessel wall.
LATE STENT MALAPPOSITION
Definition, prevalence, and mechanisms
Late stent malapposition (LSM) refers to stent malapposition that is identified at follow-up 
using IVUS or OCT. LSM can be further classified into late-persistent stent malapposition 
(LPSM) or late-acquired stent malapposition (LASM). LPSM is ASM that remains visible at 
follow-up while LASM is newly developed stent malapposition at follow-up that was not 
present immediately after stent implantation.1)2)
Table 2 summarizes the prevalence of LSM (combining LPSM and LASM) or just LASM 
or LPSM in IVUS or OCT studies: 8.3% to 31.8% for LSM and 2.7% to 30.8% for LASM. 
Importantly, LSM or LASM was higher in first-generation DES compared with bare metal 
stents (BMSs). The differentiation between LASM and LPSM requires IVUS or OCT at 
baseline and at follow-up. However, coronary artery aneurysms can be observed at follow-
up angiography.14) Because late aneurysm formation represents a type of large-sized LASM, 
a comparison of angiography between post-intervention and follow-up may be sometimes 
useful to discriminate between LPSM and LASM in patients who did not have serial 
intravascular imaging.
Positive vessel remodeling is the leading mechanism for LASM. In the IVUS report by Mintz 
et al.,15) there was an increase in external elastic membrane radius within the region of LASM, 
but no change in plaque mass. Besides regional positive vascular remodeling, abluminal 
thrombus dissolution can contribute to LASM, especially in acute coronary syndromes.1) 
Post-intervention and follow-up IVUS or OCT is required to differentiate LASM caused by 
positive remodeling vs LASM caused by thrombus dissolution.
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Table 2. Studies investigating clinical outcomes of LSM




Hoffmann et al.16) 325 Cypher/BMS IVUS 25.0%/8.3% 4 years 11.1% MACE for Cypher 16.3% MACE for Cypher No
Boden et al.49) 184 Cypher/BMS IVUS 26.6% 5 years 6.6% ST 4.3% ST Yes
Cook et al.17) 194 Cypher/Taxus IVUS 18.0% 5 years 13.5% ST 0.6% ST Yes
Im et al.50) 428 DES OCT 31.8% 6 years 6.2% MACE 11.7% MACE No
Im et al.5)33) 351 DES OCT 28.0% 8 years 7.3% MACE 10.5% MACE No
LPSM
Im et al.5)33) 351 DES OCT 19.0% 8 years 6.3% MACE 10.5% MACE No
LASM
Hong et al.21) 881 BMS IVUS 5.4% 3 years 1.9% MACE 1.8% MACE No
Tanabe et al.19) 469 Taxus SR/Taxus MR/BMS IVUS 8.0%/9.5%/5.4% 1 year No ST No ST No
Hong et al.22)23) 557 Cypher/Taxus IVUS 12.1% 3 years 3.7% MACE 2.5% MACE No
Siqueira et al.18) 195 Cypher/Taxus IVUS 5.1% 2 years 2 ST cases No ST No
van der Hoeven et al.43) 184 Cypher/BMS IVUS 25.0%/5.0% 1 year No ST No ST No
Guo et al.9) 241 Taxus/BMS IVUS 30.8%/8.1% 1 year No ST No ST No
Steinberg et al.20) 883 Taxus SR/Taxus MR/BMS IVUS 3.1%/15.4%/2.7% 2 years 8.3% MACE for Taxus 8.1% MACE for Taxus No
14.3% MACE for BMS 7.9% MACE for BMS No
Hur et al.39) 195 Cypher/Xience IVUS 16.2%/6.0% 1 year No ST No ST No
Lee et al.24) 557/881 Cypher and Taxus/BMS IVUS 12.1%/5.4% 10 years 35.5% MACE for DES 22.0% MACE for DES Yes
23.4% MACE for BMS 17.4% MACE for BMS No
BMS = bare metal stent; DES = drug-eluting stent; IVUS = intravascular ultrasound; LASM = late-acquired stent malapposition; LPSM = late-persistent stent 
malapposition; LSM = late stent malapposition; MACE = major adverse cardiac events; MR = moderate release; OCT = optical coherence tomography; SR = slow 
release; ST = stent thrombosis.
Clinical outcomes
Table 2 summarizes the clinical outcomes of LSM, LASM, or LPSM. Similar to ASM, a 
dedicated prospective study is absent; and most studies have been based on retrospective or 
sub-group analyses from randomized trials or registries. Unlike studies of ASM, results from 
studies of LSM are not consistent.
The study by Hoffmann et al.16) was a pooled analysis from the RAVEL (RAndomised 
study with the sirolimus-eluting Bx VELocity-stent), E-SIRIUS (European, multicentre, 
randomised, double-blind trial of the SIRolImUS- coated Bx VELOCITY stent in the 
treatment of patients with de novo coronary artery lesions), and SIRIUS (SIRolImUS-eluting 
stent in de novo coronary lesions) comparing sirolimus-eluting stents vs bare metal stents) 
studies. It included a total of 325 patients that had follow-up IVUS at 6 to 8 months after stent 
implantation after which 4-year clinical follow-up was available in all included patients.16) 
The frequency of MACE was 11.1% for patients with LSM vs 16.3% for those without LSM 
(p=0.48).16) In contrast to this study, Cook et al.17) reported a sub-group analysis of SIRTAX 
(Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) showing 
that very late ST out to 4 years occurred more frequently among patients with vs without 
incidentally-detected IVUS LSM at 8 months (13.5% vs 0.6%, respectively, p<0.001). 
However, the type of LSM (LPSM vs LASM) could not be differentiated in the previous 2 
studies because of the lack of post-intervention IVUS.16)17)
One registry with a small number of patients with LASM (n=10 patients) raised the possibility 
of a link between LASM and poor clinical outcomes during median 24.3 months follow-
up.18) Conversely, an IVUS study from TAXUS II showed that no ST occurred in patients 
with LASM over a period of 12 months.19) Furthermore, an integrated IVUS analysis of the 
TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent studies 
reported LASM in 7 BMS patients, 17 patients with slow-release TAXUS, and 12 patients with 
moderate-release TAXUS.20) Over the 2 ensuing years, MACE rates were similar in patients 
with vs without LASM for each of these 3 stent types.20) Two studies by Hong et al.21-23) using 
a large retrospective IVUS registry initially reported that incidentally detected LASM after 
implantation of first-generation DES or BMSs was not associated with MACE during the first 
3-year follow-up period. However, with extended follow-up out to 10 years, LASM was related 
to a greater risk of MACE (hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.04–2.67; 
p=0.03) and very late ST (HR, 3.53; 95% CI, 1.15–10.80; p=0.03) vs non-LASM in patients 
treated with first-generation DESs, but not in patients treated with bare-metal stents.24)
Virmani et al.25) reported the first case of fatal acute myocardial infarction and cardiac 
rupture as a result of late thrombosis of a first-generation sirolimus-eluting stent deployed 
18 months previously. This patient underwent IVUS immediately after stent implantation 
and at 8-month follow-up when angiographic and IVUS demonstrated enlargement of the 
stented arterial segments with LASM, indicating positive vessel remodeling.25) Autopsy 
showed aneurysmal dilatation of these segments with severe localized hypersensitivity 
consisting predominantly of T-lymphocytes and eosinophils.25) Cook et al.26) analyzed 
thrombus aspirates in patients presenting with very late DES thrombosis and demonstrated 
that eosinophils were more common in thrombi harvested from very late DES thrombosis 
vs aspirates from spontaneous acute myocardial infarction, early bare-metal ST, early DES 
thrombosis, and late bare-metal ST. The eosinophil counts also correlated with extent of 
LSM.26) Thus, chronic inflammation and hypersensitivity can weaken the vascular wall, lead 
to LASM, and induce local stasis of blood flow within the positively remodeled segments.27) 
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These inflammatory responses have been observed most frequently in the first-generation 
sirolimus-eluting stent among all coronary stents, including BMSs, other first-generation 
DES, new-generation DES, and polymer-free DESs, highlighting the clinical significance of 
polymers and drugs in DES system design.28-32)
There is little data regarding LPSM. One OCT study including 351 patients with 356 DES-
treated lesions reported that 31% of ASM remained malapposed at 6-month follow-up, and 
LPSM was not associated with 8-year MACE.5)33)
CLINICAL APPROACHES TO DRUG-ELUTING STENTS 
MALAPPOSITION
Clinical approach to acute stent malapposition
The recent consensus paper from the European Association of Percutaneous Cardiovascular 
Interventions recommended treating ASM having an axial distance ≥400 μm or longitudinal 
length ≥1 mm.34) This recommendation was based on OCT studies showing that ASM ≥400 
μm usually persists and 3 OCT-based ST registry studies showing that stent malapposition 
was one of leading mechanisms of (very) late ST.35-37) However, these registries did not have 
control groups, and OCT was performed only at the time of ST. ASM can usually be corrected 
using a balloon sized to the diameter of the arterial lumen at the site of malapposition 
inflated to nominal (not high) pressures. For percutaneous coronary intervention of 
bifurcation lesions, the recent consensus document from the European Bifurcation Club 
suggested that a stent optimization (the so-called POT technique) should be performed 
routinely during the bifurcation procedure before side branch rewiring as it facilitated access 
towards the side branch and reduced the possibility that the wire might cross into the side 
branch behind the main-branch stent along with main branch stent crush.38)
Clinical approach to late stent malapposition
There is no recommendation or consensus on proper managements of patients with 
incidentally detected LSM. However, fortunately, rapid advances of DES technology have 
made stent struts thinner and have applied biocompatible or biodegradable polymers to 
metallic struts. This progress has reduced the thrombogenicity of new-generation DES. 
From the autopsy study by Otsuka et al.,31) second-generation cobalt-chromium everolimus-
eluting stents (Xience®; Abbott Vascular, Santa Clara, CA, USA or Promus®; Boston Scientific, 
Marlborough, MA, USA) demonstrated greater strut coverage with less inflammation, 
less fibrin deposition, and less late and very late ST compared with first-generation DES. 
Clinically, these everolimus-eluting stents showed a lower frequency of LASM than first-
generation sirolimus-eluting stents at 8-month follow-up IVUS39) and were associated with 
a significant reduction of ST compared with first-generation DES.40) When the type of LSM 
is discriminated as LASM rather than LPSM, the long-term clinical outcomes appear to be 
worse. Thus, prolonged dual antiplatelet or anticoagulation therapy may be considered in 
patients having LASM. The study from Doi et al.41) showed that patients with coronary artery 
ectasia receiving optimal anticoagulation therapy did not experience the occurrence of 
MACE. Surgical resection or percutaneous angioplasty with covered stents may be considered 
for multiple or giant coronary artery aneurysms.42) In contrast to LASM, the studies by Im et 
al.5)33) suggest that treatments may not be necessary for patients with LPSM.
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CONCLUSION
The effects of DES malapposition on long-term clinical outcomes have been controversial. 
Regardless of its severity, ASM has not been associated with adverse cardiac events across all 
IVUS and OCT studies. In contrast to ASM, cumulative evidences have demonstrated that LASM 
of first-generation DES is likely to cause (very) late ST through chronic inflammatory reactions. 
This association is not clear in LPSM and may be attenuated in recent DESs which have thin 
struts and biocompatible/biodegradable polymers. Figure 2 provides the illustrative overview 
about the association between DES malapposition and long-term clinical outcomes. Although 
prolonged anti-thrombotic therapy and/or percutaneous intervention using large-sized balloon 
or covered stent may be considered in patients with LASM, the treatments should be made 
considering the clinical situations of individual patient due to lack of firm evidences.
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